Palisade Bio reported second quarter 2026 financial results and advanced PALI-2108 into Phase 2 development. Advancing PALI-2108 into Phase 2 marks a major pipeline milestone with potential to shift company trajectory.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | 2 | — | — | — | — | — | 3 | — | — |
| Sell | — | — | — | — | 2 | — | — | — | — | 2 | — | — |
| total | individual payouts | |
|---|---|---|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 12.43 | 9.82 | 133.39 | 125.17 |
| Receivables | — | — | — | 0.50 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 13.33 | 10.49 | 134.22 | 127.26 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.70 | 1.11 | 0.77 | 1.84 |
| ST’ Debt | 0.16 | 0.08 | 0.38 | — |
| Other | — | — | — | — |
| 2.59 | 3.24 | 4.64 | 5.25 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | 0.50 | — | — |
—
|
| ’23 | 0.25 | — | — | — |
0.25
|
| ’20 | 0.01 | 0.00 | 0.00 | 0.00 |
0.01
|
| ’19 | 0.00 | 0.01 | 0.00 | 0.00 |
0.02
|
| ’18 | 0.00 | 0.25 | 0.00 | 0.00 |
0.26
|
| ’17 | 0.00 | 0.00 | 0.00 | 0.25 |
0.26
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.89) | (7.60) | — | — |
—
|
| ’25 | (2.33) | (1.82) | (3.55) | (3.14) |
(10.85)
|
| ’24 | (3.18) | (3.50) | (3.13) | (2.38) |
(12.19)
|
| ’23 | (3.53) | (2.20) | (2.66) | (2.75) |
(11.13)
|
| ’22 | (3.76) | (3.25) | (3.04) | (3.31) |
(13.36)
|
| ’21 | (1.25) | (7.72) | (2.75) | (3.05) |
(14.77)
|
| ’20 | (1.68) | (0.67) | (0.87) | (1.55) |
(4.77)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.89) | (7.60) | — | — |
—
|
| ’25 | (2.33) | (1.82) | (3.55) | (3.14) |
(10.85)
|
| ’24 | (3.18) | (3.50) | (3.13) | (2.38) |
(12.19)
|
| ’23 | (3.53) | (2.20) | (2.66) | (2.75) |
(11.14)
|
| ’22 | (3.76) | (3.25) | (3.04) | (3.32) |
(13.37)
|
| ’21 | (1.25) | (7.72) | (2.75) | (3.05) |
(14.77)
|
| ’20 | (1.68) | (0.68) | (0.87) | (1.55) |
(4.77)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.05) | (0.05) | — | — |
—
|
| ’25 | (0.47) | (0.58) | (0.38) | — |
(0.30)
|
| ’24 | (4.59) | (3.32) | (2.32) | (0.69) |
(10.19)
|
| ’23 | (8.10) | (7.95) | (7.35) | (3.75) |
(26.99)
|
| ’22 | (194.90) | (89.95) | (59.97) | (1.36) |
(247.83)
|
| ’21 | (4.75) | (3.07k) | 314.84 | 554.72 |
(2.54k)
|
| ’20 | (4.18k) | (674.53) | (584.59) | (1.08k) |
(5.26k)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 26.10 | 7.50 | 1.38 | 0.53 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,215.00 | 69.90 | 22.35 | 2.64 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | 12 | 9 | 8 | 14 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00 | 0.03 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | 0.25 | — | — | — | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00% | 100.00% | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.26) | (12.30) | (14.44) | (16.78) | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00% | (4,920.00%) | 0.00% | 0.00% | — | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.26) | (12.30) | (14.44) | (16.78) | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00 | 0.55 | 0.00 | 0.00 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (247.83) | (26.99) | (10.19) | (0.30) | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (227.60) | (24.41) | (8.61) | (0.19) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | (0.17) | (0.01) | 0.00 | 0.00 | — | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (227.77) | (24.42) | (8.61) | (0.19) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 212.59 | 24.81 | 5.29 | 2.32 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.06 | 0.46 | 1.42 | 55.67 | — | — | — |
Shares
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | — | 0.00 | — | — | — | — | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | 15.41 | — | — | — | — | — |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | — | — | 0.35 | — | — | — | — | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | (31.79) | — | — | — | — | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | 0.73 | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.36) | (11.13) | (12.19) | (10.85) | — | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | (0.01) | 0.00 | — | — | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.37) | (11.14) | (12.19) | (10.85) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.72 | 10.74 | 7.26 | 129.59 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.30 | 0.16 | 0.08 | 0.38 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.08) | (12.27) | (9.74) | (133.00) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 12.48 | 11.31 | 7.49 | 129.38 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (100.87%) | (82.62%) | (115.82%) | (23.11%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | (2,487.50%) | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (143.75%) | (103.55%) | (153.59%) | (24.52%) | — | — | — |
ROE
|
Palisade Bio (PALI), a lean biotech powerhouse with just 8 employees, is charging ahead with its lead asset PALI-1801—a promising PDE4 inhibitor targeting postoperative ileus and ulcerative colitis in a massive $10B+ market. Despite classic sector headwinds like razor-thin revenue, ballooning losses, and eye-watering share dilution (up over 1.3 million% since 2016), the company’s cash-rich balance sheet and negligible debt provide a solid runway for Phase 3 trials kicking off in 2024. Recent insider buys, including a director snapping up 10,000 shares at depressed prices, scream undervaluation and insider conviction in the pipeline’s breakout potential.
The stock’s rollercoaster—from 2023 hype-fueled highs of $69.90 to today’s penny-stock lows—mirrors trial updates and dilution fatigue, but metrics like a PB ratio of 0.35 and wild EV/FCF swings signal a screaming bargain for risk-tolerant growth seekers. With working capital funding 6-9 months of burn and historical gross margins hitting 100% on rare revenue blips, PALI is primed for an inflection if clinical stars align.
Analysts are buzzing with moonshot targets: average 480% upside, highs at 1,350% from here, betting on Phase 3 data in 2026 to ignite multibagger returns akin to past GI biotech winners. Dive into the full analysis for the charts, correlations, and catalysts that could turn this dilution-scarred underdog into a redemption story.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.